📣 VC round data is live. Check it out!

Tandem Diabetes Care Valuation Multiples

Discover Tandem Diabetes Care's revenue and EBITDA valuation multiples, acquisitions, and investment history, alongside public comparables like SonoScape, Sinocare, Enovis, AtriCure and more.

Tandem Diabetes Care Overview

About Tandem Diabetes Care

Tandem Diabetes designs, manufactures, and markets durable insulin pumps for individuals with diabetes. The firm first entered this market in 2012 and has since introduced multiple generations of pumps leading to its current t:slim X2 device. The firm recently launched its smaller Mobi pump and continues to work on Tobi (a tubeless version of Mobi), and the Sigi tubeless patch pump. Nearly three-quarters of total revenue is derived from the US, with the remainder primarily from other developed nations. The pumps themselves generate just over half of total sales, and another one-third is from disposable infusion sets that need to be changed over every 2 to 3 days.


Founded

2008

HQ

United States

Employees

2.5K

Financials (LTM)

Revenue: $1B
EBITDA: ($3M)

EV

$1B

Valuation Multiples

Start free trial

Valuation Multiples for 15K+ Public Comps

AdidasAirbnbAmazonCiscoCoca-ColaDellDropboxIBMIntelMcDonaldsNikeNVIDIASamsungSpotifyTeslaToyota
Browse Valuation Multiples

Tandem Diabetes Care Financials

Tandem Diabetes Care reported last 12-month revenue of $1B and negative EBITDA of ($3M).

In the same LTM period, Tandem Diabetes Care generated $572M in gross profit, ($3M) in EBITDA losses, and had net loss of ($120M).

Revenue (LTM)


Tandem Diabetes Care P&L

In the most recent fiscal year, Tandem Diabetes Care reported revenue of $1B and EBITDA of ($46M).

Tandem Diabetes Care is unprofitable as of last fiscal year, with gross margin of 54%, EBITDA margin of (5%), and net margin of (17%).

See analyst estimates for Tandem Diabetes Care
LTMLast FY202320242025202620272028
Revenue$1B$1B$748M$940M$1B
Gross Profit$572M$546M$368M$490M$546M
Gross Margin55%54%49%52%54%
EBITDA($3M)($46M)($196M)($70M)($177M)
EBITDA Margin(0%)(5%)(26%)(7%)(17%)
EBIT Margin(11%)(16%)(31%)(11%)(16%)
Net Profit($120M)($174M)($223M)($96M)($205M)
Net Margin(12%)(17%)(30%)(10%)(20%)
Net Debt-$219M---

Financial data powered by Morningstar, Inc.

Tandem Diabetes Care Stock Performance

Tandem Diabetes Care has current market cap of $1B, and enterprise value of $1B.

Market Cap Evolution


Tandem Diabetes Care's stock price is $18.61.

Tandem Diabetes Care share price increased by 8.2% in the last 30 days, and decreased by 0.2% in the last year.

Tandem Diabetes Care has an EPS (earnings per share) of $-2.53.

See more trading valuation data for Tandem Diabetes Care
EVMarket CapPrice 1DPrice 1MPrice 3MPrice 12MEPS
$1B$1B-2.6%8.2%-2.9%-0.2%$-2.53

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.

Start Free Trial

Tandem Diabetes Care Valuation Multiples

Tandem Diabetes Care trades at 1.4x EV/Revenue multiple, and (430.9x) EV/EBITDA.

See NTM and 2027E valuation multiples for Tandem Diabetes Care

EV / Revenue (LTM)


Tandem Diabetes Care Financial Valuation Multiples

As of June 3, 2026, Tandem Diabetes Care has market cap of $1B and EV of $1B.

Tandem Diabetes Care has a P/E ratio of (10.6x).

LTMLast FY202320242025202620272028
EV/Revenue1.4x1.4x1.9x1.5x1.4x
EV/EBITDAn/m(31.2x)(7.3x)(20.6x)(8.2x)
EV/EBIT(12.3x)(8.6x)(6.2x)(14.5x)(8.6x)
EV/Gross Profit2.5x2.6x3.9x2.9x2.6x
P/E(10.6x)(7.3x)(5.7x)(13.3x)(6.2x)
EV/FCFn/mn/m(17.3x)n/m(13.3x)

Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Verified Tandem Diabetes Care Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.

FactSetMorningstar
Start Free Trial

Tandem Diabetes Care Margins & Growth Rates

Tandem Diabetes Care grew revenue by 6% but EBITDA decreased by 220% in the last fiscal year.

In the most recent fiscal year, Tandem Diabetes Care reported gross margin of 54%, EBITDA margin of (5%), and net margin of (17%).

See estimated margins and future growth rates for Tandem Diabetes Care

Tandem Diabetes Care Margins

Last FY202420252026202720282029
Gross Margin54%52%54%57%
EBITDA Margin(5%)(7%)(17%)5%
EBIT Margin(16%)(11%)(16%)(4%)
Net Margin(17%)(10%)(20%)(4%)
FCF Margin0%1%(11%)(0%)

Tandem Diabetes Care Growth Rates

FY+1/FY23/2424/2525/2626/2727/2828/29
Revenue Growth6%26%8%6%
Gross Profit Growth11%33%12%11%
EBITDA Growth(220%)(64%)153%(131%)
EBIT Growth(76%)(57%)69%(76%)
Net Profit Growth(73%)(57%)113%(77%)
FCF Growth(358%)(106%)(2268%)(96%)

Data powered by FactSet, Inc. and Morningstar, Inc.

Tandem Diabetes Care Operational KPIs

Tandem Diabetes Care's revenue per employee in the last FY averaged $0.4M, while opex per employee averaged $0.3M for the same period.

Tandem Diabetes Care's Rule of 40 is 11% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Tandem Diabetes Care's Rule of X is 20% (created by Bessemer, Rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

Access forward-looking KPIs for Tandem Diabetes Care
LTMLast FY202320242025202620272028
Rule of 408%11%---
Bessemer Rule of X21%20%---
Revenue per Employee-$0.4M---
Opex per Employee-$0.3M---
R&D Expenses to Revenue19%26%33%21%26%
Opex to Revenue-70%80%63%70%

Data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 230+ Verticals

Tandem Diabetes Care Competitors

Tandem Diabetes Care competitors include SonoScape, Sinocare, Enovis, AtriCure, AdaptHealth, Integra Lifesciences, Wandong Medical, VCANBIO, Shinva and Butterfly Network.

Most Tandem Diabetes Care public comparables operate across Medical Devices, DeepTech and HealthTech.

EV/RevenueEV/EBITDA
Last FYLTM2027ELast FYLTM2027E
SonoScape3.3x3.1x27.8x24.6x
Sinocare1.9x1.8x22.4x17.2x
Enovis1.2x1.2x6.6x6.4x
AtriCure2.3x2.2x20.0x17.7x
AdaptHealth1.0x1.0x5.3x5.0x
Integra Lifesciences1.8x1.8x9.5x9.3x
Wandong Medical4.5x4.3x(24.0x)-
VCANBIO5.1x-22.3x-

This data is available for Pro users. Sign up to see all Tandem Diabetes Care competitors and their valuation data.

Start Free Trial

Acquisitions by Tandem Diabetes Care

Tandem Diabetes Care has acquired 3 companies to date.

Last acquisition by Tandem Diabetes Care was on December 13th 2022. Tandem Diabetes Care acquired AMF Medical for $207M (EV/Revenue multiple available to Pro users).

See M&A valuation multiples

Latest Acquisitions by Tandem Diabetes Care

AMF Medical
Capillary Biomedical
Sugarmate
Description
AMF Medical is a Lausanne-based medical device company that develops Sigi, a wearable insulin patch pump designed for diabetes management with integration to continuous glucose monitors and automated dosing algorithms. Separated from Advanced Microfluidics in 2021, the company focuses on user-friendly insulin delivery systems that connect to apps for remote monitoring. AMF Medical advances closed-loop therapy solutions for type 1 diabetes patients.
Capillary Biomedical is a medical device company headquartered in Irvine, California, that develops implantable insulin delivery systems for diabetes management. Its lead product, the i-Pump, delivers insulin directly into the peritoneal cavity to mimic natural pancreatic function more effectively than subcutaneous methods. As a spin-out from the Artificial Pancreas Center at Sidney Kimmel Medical College of Thomas Jefferson University in Philadelphia, the company focuses on simplifying continuous glucose monitoring and automated insulin dosing. Capillary Biomedical has raised funding through grants from the National Institutes of Health and partnerships with diabetes research organizations.
Sugarmate is a smartphone application tailored for Dexcom G6 and G7 continuous glucose monitor users managing type 1 diabetes. The iOS and Apple Watch app visualizes glucose trends through customizable graphs, delta alerts, and bolus calculators. Sugarmate syncs data from iPhones to share reports with caregivers and endocrinologists via email or HealthKit integration.
HQ CountrySwitzerlandUnited StatesUnited States
HQ City
Lausanne
Los Angeles, CA
New York City, NY
Deal Date13 Dec 202221 Jul 202224 Jun 2020
Valuation$207M$29Mundisclosed
EV/Revenue
EV/EBITDA

This data is available for Pro users. Sign up to see all Tandem Diabetes Care acquisitions and their M&A valuation multiples.

Start Free Trial

Investments by Tandem Diabetes Care

Tandem Diabetes Care has invested in 2 companies to date.

Latest investment by Tandem Diabetes Care was on September 1st 2022. Tandem Diabetes Care invested in AMF Medical in their $8M Strategic investment round (EV/Revenue multiple available to Pro users).

See VC round multiples

Latest Investments by Tandem Diabetes Care

AMF Medical
CeQur Simplicity
Description
AMF Medical is a Lausanne-based medical device company that develops Sigi, a wearable insulin patch pump designed for diabetes management with integration to continuous glucose monitors and automated dosing algorithms. Separated from Advanced Microfluidics in 2021, the company focuses on user-friendly insulin delivery systems that connect to apps for remote monitoring. AMF Medical advances closed-loop therapy solutions for type 1 diabetes patients.
CeQur Simplicity is a Zug, Switzerland-based medical device company developing wearable bolus insulin delivery patches for type 2 diabetes management. The Simplicity platform delivers up to three days of automated dosing via button-activated patches, distributed through partnerships with pharmaceutical firms in Europe and the United States.
HQ CountrySwitzerlandSwitzerland
HQ City
Lausanne
Lucerne
Deal Date1 Sep 202213 Apr 2021
RoundStrategic investmentSeries C
Raised$8M$115M
InvestorsTandem Diabetes CareCredit Suisse Entrepreneur Capital; Endeavour Vision; Federated Kaufmann Fund; GMS Capital Partners; Kingdon Capital; Schroders; Tandem Diabetes Care; VI Partners; Ypsomed
Valuationundisclosedundisclosed
EV/Revenue
EV/EBITDA

This data is available for Pro users. Sign up to see all Tandem Diabetes Care investments and their VC round multiples.

Start Free Trial

Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples

Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.

Start Free Trial

About Tandem Diabetes Care

When was Tandem Diabetes Care founded?Tandem Diabetes Care was founded in 2008.
Where is Tandem Diabetes Care headquartered?Tandem Diabetes Care is headquartered in United States.
How many employees does Tandem Diabetes Care have?As of today, Tandem Diabetes Care has over 2K employees.
Who is the CEO of Tandem Diabetes Care?Tandem Diabetes Care's CEO is John F. Sheridan.
Is Tandem Diabetes Care publicly listed?Yes, Tandem Diabetes Care is a public company listed on Nasdaq.
What is the stock symbol of Tandem Diabetes Care?Tandem Diabetes Care trades under TNDM ticker.
When did Tandem Diabetes Care go public?Tandem Diabetes Care went public in 2013.
Who are competitors of Tandem Diabetes Care?Tandem Diabetes Care main competitors include SonoScape, Sinocare, Enovis, AtriCure, AdaptHealth, Integra Lifesciences, Wandong Medical, VCANBIO, Shinva, Butterfly Network.
What is the current market cap of Tandem Diabetes Care?Tandem Diabetes Care's current market cap is $1B.
What is the current revenue of Tandem Diabetes Care?Tandem Diabetes Care's last 12 months revenue is $1B.
What is the current revenue growth of Tandem Diabetes Care?Tandem Diabetes Care revenue growth (NTM/LTM) is 9%.
What is the current EV/Revenue multiple of Tandem Diabetes Care?Current revenue multiple of Tandem Diabetes Care is 1.4x.
Is Tandem Diabetes Care profitable?No, Tandem Diabetes Care is not profitable.
What is the current EBITDA of Tandem Diabetes Care?Tandem Diabetes Care has negative EBITDA and is not profitable.
What is Tandem Diabetes Care's EBITDA margin?Tandem Diabetes Care's last 12 months EBITDA margin is (0%).
What is the current EV/EBITDA multiple of Tandem Diabetes Care?Current EBITDA multiple of Tandem Diabetes Care is (430.9x).
What is the current FCF of Tandem Diabetes Care?Tandem Diabetes Care's last 12 months FCF is ($773K).
What is Tandem Diabetes Care's FCF margin?Tandem Diabetes Care's last 12 months FCF margin is (0%).
What is the current EV/FCF multiple of Tandem Diabetes Care?Current FCF multiple of Tandem Diabetes Care is (1862.8x).
How many companies Tandem Diabetes Care has acquired to date?As of June 2026, Tandem Diabetes Care has acquired 3 companies.
What was the largest acquisition by Tandem Diabetes Care?$207M acquisition of AMF Medical on 13th December 2022 was the largest M&A Tandem Diabetes Care has done to date.
What companies Tandem Diabetes Care acquired?Tandem Diabetes Care acquired AMF Medical, Capillary Biomedical, and Sugarmate.
In how many companies Tandem Diabetes Care has invested to date?As of June 2026, Tandem Diabetes Care has invested in 2 companies.
What was the last Tandem Diabetes Care investment?On 1st September 2022 Tandem Diabetes Care invested in AMF Medical, participating in a $8M Strategic investment round.
In what companies Tandem Diabetes Care invested in?Tandem Diabetes Care invested in CeQur Simplicity and AMF Medical.

See public comps similar to Tandem Diabetes Care

Lists including Tandem Diabetes Care

Start Your
Free Trial Today

Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.

Start Trial